Sucampo Pharma (SCMP) Tops Q2 EPS by 2c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/24/2026
- Wall Street closes lower to end rocky week
- Meta's capital-raising plans expose a major weakness in the AI boom
- Oil prices jump $3 on Houthi attacks, oil spill, highest settlement since April
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
Sucampo Reports First Quarter 2015 Financial Results and Corporate Update
May 6, 2015 6:30 AM EDTStrong Financial Performance Driven by Continued Revenue and Sales Growth of AMITIZA
Strong Growth in Net Income and EPS
Company Confirms 2015 Earnings Guidance
Company to Host Conference Call Today at 8:30 a.m. Eastern
BETHESDA, Md., May 6, 2015 (GLOBE NEWSWIRE) -- Sucampo Pharmaceuticals, Inc. (Sucampo) (Nasdaq: SCMP) today reported consolidated financial results for the first quarter ended March 31, 2015.
Sucampo reported year-over-year growth of 33% to $29.5 million in total revenue, 17% to $15.7... More



